^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Small Cell Lung Cancer
    Drug:Tecentriq (atezolizumab) (PD-L1 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A1 - Approval
    New
    Source:
    Scottish Medicines Consortium
    Title:

    Atezolizumab (Tecentriq®) is accepted for use within NHSScotland

    Published date:
    10/09/2020
    Excerpt:
    Atezolizumab, in combination with carboplatin and etoposide, is indicated for the first-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC).
    Secondary therapy:
    carboplatin + etoposide IV
    Evidence Level:
    Sensitive: A1 - Approval
    Source:
    FDA
    Excerpt:
    TECENTRIQ is a programmed death-ligand 1 (PD-L1) blocking antibody indicated:...in combination with carboplatin and etoposide, for the first-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC).
    Secondary therapy:
    carboplatin + etoposide IV
    Evidence Level:
    Sensitive: A2 - Guideline
    Source:
    ESMO.org
    Title:

    Small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

    Published date:
    04/14/2021
    Excerpt:
    Recommendations: An anti-PD-L1 inhibitor (atezolizumab [I, A; ESMO-MCBS v1.1 score: 3] or durvalumab [I, A; ESMO-MCBS v1.1 score: 3]) in combination with four to six cycles of a platinum and etoposide can be offered to all patients with treatment-naive extensive-stage SCLC, a PS of 0-1 and no contraindications for immunotherapy [I, A].
    Secondary therapy:
    etoposide IV
    DOI:
    10.1016/j.annonc.2021.03.207
    Evidence Level:
    Sensitive: A2 - Guideline
    Source:
    NCCN
    Excerpt:
    The NCCN SCLC Panel recommends (category 1) carboplatin plus etoposide plus atezolizumab as a preferred first-line systemic therapy option followed by maintenance atezolizumab for patients with extensive-stage SCLC...
    Secondary therapy:
    carboplatin + etoposide IV